Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
This was a multi-center open label study to provide continued supply of QTI571 to patients in Japan who were treated in the extension study (A2301E1) and were judged by the investigator to benefit from continued QTI571 treatment.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
patient is receiving QTI571 for the treatment of Pulmonary Arterial Hypertension (PAH) and is currectly enrolled in a long-term extension study (CQTI571A2301E1) in Japan.
Patient is currently benifitting form the treatment with QTI571 in the opinion of the investigator.
You may not be if
Patient has been permanently discontinued from QTI571 study treatment in the parent study.
Concomitant use of oral vitamin K antagonist medication.
Clareo Health | Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan
